Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Undefined

ABSTRACT: Transcriptional profiling of engineered yeast strains for protein secretion

PROVIDER: PRJEB53464 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR9836390_1.fastq.gz	Fastqsanger.gz
	ERR9836390_2.fastq.gz	Fastqsanger.gz
	ERR9836391_1.fastq.gz	Fastqsanger.gz
	ERR9836391_2.fastq.gz	Fastqsanger.gz
	ERR9836392_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Project description:Transcriptional profiling of yeast strains with various levels of protein secretion

| PRJEB17688 | ENA

Metabolic engineering of Saccharomyces cerevisiae and role of transcription factor Znf1

Project description:Agricultural wastes and other non-food sources can be used to produce biofuels. Despite multiple attempts using engineered yeast strains expressing exogenous genes, the native Saccharomyces cerevisiae produces low amount of second generations of biofuels. Here, we focused on Znf1, a non-fermentable carbon transcription factor and the suppressor protein Bud21 to overcome this challenge. Several mutants of engineered S. cerevisiae strains were engineered to enhance production of biofuels and xylose-derived compounds such as xylitol. This study demonstrates Znf1's novel transcriptional regulatory control of xylose and offer an initial step toward a more sustainable production of advanced biofuels from xylose.

2024-01-21 | PXD048648 | Pride

Project description:Transcriptional sequencing of engineered yeast

| PRJNA967798 | ENA

Expression data of antibody fragments from Saccharomyces cerevisiae

Project description:Saccharomyces cerevisiae has been used as a secretion host for production of various products, including pharmaceuticals. However, few antibody molecules have been functionally expressed in S. cerevisiae due to the incompatible surface glycosylation. Our laboratory previously isolated a group of yeast mutant strains with different α-amylase secretory capacities, and these evolved strains have showed advantages for production of some heterologous proteins. However, it is not known whether these secretory strains are generally suitable for pharmaceutical protein production. Here, three non-glycosylated antibody fragments with different configurations (Ran-Fab fragment Ranibizumab, Pex-the scFv peptide Pexelizumab, and Nan-a single V-type domain) were successfully expressed and secreted in three background strains with different secretory capacities, including HA (wild type), MA (evolved strain), and LA (evolved strain). However, the secretion of Ran and Nan were positively correlated with the strains’ secretory capacity, while Pex was most efficiently secreted in the parental strain. Therefore, transcriptional analysis was performed to explore the fundamental changes triggered by the expression of the different pharmaceutical proteins in these selected yeast strains.

2021-07-06 | GSE179391 | GEO

Disomes and Disomes ubp6∆ vs. wild-type

Project description:Transcriptional profiling of anreuploid yeast strains grown in rich medium YEPD

2014-02-20 | GSE55166 | GEO

Disomes and Disomes lcb3∆ vs. wild-type

Project description:Transcriptional profiling of aneuploid yeast strains grown in rich medium YEPD

2017-01-19 | GSE93762 | GEO

RNA-seq analysis of model-guided engineered Saccharomyces cerevisiae chassis for improved dicarboxylic acids (malic, succinic and fumaric acid) production.

Project description:Model-guided chassis strain design has the potential to accelerate cellfactory development. In this experiment genetic targets were identified in silico and implemented in vivo to design a yeast chassis strain for enhanced production of succinic, malic and fumaric acid. The phenotype of engineered chassis strains was further optimised through adaptive laboratory evolution. RNA-seq analysis of engineered yeast chassis strains, evolved strains and wild-type (CEN.PK background)was performed to determine the effect of engineered gene deletions and evolution on the transcriptome.

2021-07-01 | E-MTAB-9499 | biostudies-arrayexpress

Metabolically engineered urea degrading and urea importing Sake yeast strains K7 (WT), K7 Dur1,2 and K7 Dur3

Project description:Excess/residual urea is a pervasion problem in wine and Sake fermentation. We sought to reduce residual urea levels (to reduce ethyl carbamate leves) by engineering the Sake yeast strain K7 to constitutively express either the urea amidolyase (Dur1,2) or urea importer (Dur3). We sought to then compare the gene expression profiles of the metabolically engineered yeast strains to the parental strain during fermentation. Engineered strains would hopefully have gene expression profiles that were minimally different from the parental strain.

2010-04-21 | GSE17867 | GEO

Project description:Non-engineered yeast strains from the Prymetime publication

| PRJNA694170 | ENA

Engineered yeast strains expressing human glycolytic enzymes

Project description:Ewout Knibbe et al.,(Pascale Daran-Lapujade Lab, TU Delft) report on engineered yeast strains to express the human glycolysis pathway instead of the native pathway enzymes. The goal of the project is to investigate the conservation of these functions between species. The engineered yeast strains were compared to their native strains in regard to growth rate and glycolytic flux, and by means of omics such as by large-scale quantitative proteomics.

2021-12-22 | PXD025349 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data